Boryun-Roche target anticancer market together

Boryung Pharm and Roche will target the anticancer market with hands together.

According to the industry concerned on the 18^th, Boryung Pharm was known to jointly sell the Roche Korea’s non-small cell lung cancer therapy, Tarceva(generic name: erlotinib).  

The agreement between the two companies has attracted attention of the industry since its patent will be expired on the coming 30^th and m...